COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020

Covid19 Clinical Trial

Official title:

SARS-CoV-2 Seroconversion Study Among GHdC Staff Members

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04723290
• Other study ID #: SERO-SARS-CoV-2 GHdC
• Status: Completed
• Phase: N/A
• Start date: June 20, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: March 2021
• Source: Grand Hôpital de Charleroi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been in contact with the SARS CoV-2 virus for organizational and evaluation purposes symptoms.

Description:

At the start of the SARS-CoV-2 pandemic, several workers had symptoms compatible with COVID-19 at a time when PCR (smear) testing was only allowed for hospitalized people. In addition, the PCR test has a fairly low sensitivity. In this context, serology can make it possible to determine whether the symptoms are indeed linked to exposure to SARS-CoV-2.

As a hospital, and in order to prepare for a possible second epidemic wave, it is also useful to know the proportion of staff members who have already been in contact with the virus for organizational purposes and symptom assessment.

.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2817
• Est. completion date: December 31, 2020
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be a member of the staff of the Grand Hôpital de Charleroi who wishes to participate in order to know their immunity related to SARS CoV-2 after the first wave of pandemic.

Exclusion Criteria:

• Not be part of the staff of the Grand Hôpital de Charleroi.

Related Conditions & MeSH terms

• Covid19

Intervention

Diagnostic Test:
• Serological tests for SARS Cov-2
Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood

Locations

Country	Name	City	State
Belgium	Grand Hôpital de Charleroi	Charleroi	Hainaut

Sponsors (1)

Lead Sponsor	Collaborator
Grand Hôpital de Charleroi

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serological tests to know the level of antibodies against SARS CoV-2	The hospital has organized several schedules and appointments for each staff member depending on the ability to analyze laboratory samples and blood draws.	up to 6 weeks